<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Oxybutynin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01062</strong>&#160; (APRD00427)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01062/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01062/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01062.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01062.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01062.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01062.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01062.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01062">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Oxibutinina</td><td>Spanish</td><td>INN</td></tr><tr><td>Oxybutynine</td><td>French</td><td>INN</td></tr><tr><td>Oxybutyninum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Oxybutynin Chloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000430/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000430/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: SWIJYDAEGSIQPZ-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 393.207071602</li>
              <li>Average Mass: 393.947</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000430">DBSALT000430</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Ditropan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gelnique</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lenditro</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lyrinel XL</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Oxytrol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/muscarinic-antagonists">Muscarinic Antagonists</a></li>
<li><a href="/mesh/parasympatholytics">Parasympatholytics</a></li>
<li><a href="/mesh/cholinergic-antagonists">Cholinergic Antagonists</a></li>
<li><a href="/mesh/antispasmodics">Antispasmodics</a></li>
<li><a href="/mesh/muscle-relaxants-genitourinary">Muscle Relaxants, Genitourinary</a></li></ul></td></tr><tr><th>CAS number</th><td>5633-20-5</td></tr><tr><th>Weight</th><td>Average: 357.4864<br>Monoisotopic: 357.230393863</td></tr><tr><th>Chemical Formula</th><td>C<sub>22</sub>H<sub>31</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>XIQVNETUBQGFHX-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenylacetic Acid Derivatives</td></tr><tr><th>Direct parent</th><td>Phenylacetic Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Tertiary Alcohols; Tertiary Amines; Carboxylic Acid Esters; Ethers; Enolates; Polyamines; Aldehydes</td></tr><tr><th>Substituents</th><td>tertiary alcohol; tertiary amine; carboxylic acid ester; enolate; carboxylic acid derivative; ether; polyamine; organonitrogen compound; amine; alcohol; aldehyde</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of overactive bladder.</td></tr><tr><th>Pharmacodynamics</th><td>Oxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. Antimuscarinic activity resides predominantly in the R-isomer.</td></tr><tr><th>Mechanism of action</th><td>Oxybutynin exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects). By inhibiting particularily the M1 and M2 receptors of the bladder, detrusor activity is markedly decreased.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed from gastrointestinal tract.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>193 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>91%-93%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, primarily by CYP3A4</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Oxybutynin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00381">N-desethyloxybutynin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/383">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine.
Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.</td></tr><tr><th>Half life</th><td>12.4-13.2 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=1220 mg/kg (Orally in rats, Goldenthal)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9225</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9418</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5989</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7244</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.6809</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.7244</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.558</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.812</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7985</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5213</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9106</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8949</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.7137</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7038
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9878
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9059 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9548
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7337
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Watson laboratories inc</li>
<li>Ortho mcneil janssen pharmaceuticals inc</li>
<li>Mikart inc</li>
<li>Novex pharma</li>
<li>Pharmaceutical assoc inc div beach products</li>
<li>Silarx pharmaceuticals inc</li>
<li>Vintage pharmaceuticals inc</li>
<li>Wockhardt eu operations (swiss) ag</li>
<li>Impax pharmaceuticals</li>
<li>Mylan pharmaceuticals inc</li>
<li>Osmotica pharmaceutical corp</li>
<li>Pliva inc</li>
<li>Quantum pharmics ltd</li>
<li>Usl pharma inc</li>
<li>Janssen Pharmaceuticals, Inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Alza Corp.</li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Dept Health Central Pharmacy</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li>Goldline Laboratories Inc.</li>
<li><a href="http://www.impaxlabs.com">Impax Laboratories Inc.</a></li>
<li><a href="http://www.janssen-ortho.com">Janssen-Ortho Inc.</a></li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li>McNeil Laboratories</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho Mcneil Janssen Pharmaceutical Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li>Schwarz Pharma Inc.</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>USL Pharma Inc.</li>
<li>Vangard Labs Inc.</li>
<li>Vintage Pharmaceuticals Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Patch</td><td>Transdermal</td><td></td></tr><tr><td>Syrup</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Oxybutynin may cause carbamazepine toxicity</td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00989">Rivastigmine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Oxybutynin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.</td></tr><tr><td><a href="/drugs/DB00662">Trimethobenzamide</a></td><td>Trimethobenzamide and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>Trospium and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>